CN103933576A - Preparation method of paeonol preparation - Google Patents
Preparation method of paeonol preparation Download PDFInfo
- Publication number
- CN103933576A CN103933576A CN201410124917.2A CN201410124917A CN103933576A CN 103933576 A CN103933576 A CN 103933576A CN 201410124917 A CN201410124917 A CN 201410124917A CN 103933576 A CN103933576 A CN 103933576A
- Authority
- CN
- China
- Prior art keywords
- paeonol
- add
- medical material
- preparation
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a clathrate compound of paeonol. The clathrate compound is a mixture of beta-cyclodextrin and hydroxypropyl beta-cyclodextrin; the mol ratio of beta-cyclodextrin to hydroxypropyl beta-cyclodextrin is 10:1 to 1:1; the mol ratio of clathrate to the clathrate compound is 1:2 to 1:10. The water solubility of the clathrate compound of paeonol is greatly increased, and the stability is strong, so that the clathrate compound of paeonol is difficult to release; the bitter taste masking effect is good; the inclusion rate can be above 80%.
Description
The present patent application is application number 201210292211.8, the applying date on 08 16th, 2012, the divisional application of denomination of invention " a kind of paeonol clathrate and preparation method thereof ".
Technical field
The invention belongs to pharmaceutical preparations technology field, be specifically related to a kind of paeonol preparation, more specifically relate to a kind of preparation method of paeonol enclose preparation.
Technical background
Paeonol be Paeoniaceae plant Paeonia suffruticosa (
paeonia moutansim.) skin, Asclepiadaceae plant Radix Cynanchi Paniculati (
pycnostelma paniculatumk. Schum) herb in main active, its chemical formula is Paeonolum, molecular formula is C
9h
10o
3, relative molecular mass is 166.18.Paeonol is white or micro-yellow crystal or crystalline powder, has special smellyly, and taste is micro-peppery, is soluble in ethanol and methanol, in hot water, dissolves, and is insoluble to cold water, can volatilize with water vapour, and 48 DEG C～51 DEG C of fusing points.Paeonol pharmacologically active is extensive, has analgesia, antiinflammatory, antipyretic and suppress the effects such as allergy, calmness, hypnosis, antibacterial, antiinflammatory, antioxidation, blood pressure lowering, the clinical diseases such as cardiovascular and cerebrovascular vessel, allergy, inflammation and immune system that are used for; Aspect daily use chemicals, paeonol can suppress oxygen-derived free radicals in cell and produce, and can make skin whitening, and by fossil pigments Reduction fading in skin, the effects such as silt dissipating rashes, antiinflammatory, reducing swelling and alleviating pain, antiallergic, antiviral disappear.Mottle, myalgia, skin pruritus, psoriasis, zona shingles, eczema are had to good treatment and health-care effect, in addition, in toothpaste, gargarism, dentifrice, toothache drops, have good effect.Due to paeonol have special smelly, high volatility, all unstable to illumination, temperature and humidity, poorly water-soluble, be unfavorable for directly applying to medicine and daily use chemicals aspect, often adopt the mode of enclose to process it.The preparation method that clathrate is conventional has saturated water solution method, ultrasonic method, polishing, freeze-drying, spray drying method etc.
When existing research is carried out physical modification to paeonol, adopt beta-schardinger dextrin-to carry out enclose to it more.But cause its poorly water-soluble (25 DEG C, 1.85g/100ml) owing to having formed intramolecular hydrogen bond between C – 2 in beta-schardinger dextrin-molecule and C – 3 hydroxyls, make it to be restricted in many application.Still there is taste masking poor effect in the paeonol clathrate of preparation at present, and inclusion rate is low, unstable, the problems such as poorly water-soluble.
Summary of the invention
The object of the present invention is to provide a kind of preparation method of paeonol preparation, the paeonol clathrate inclusion rate of preparation is high, taste masking effect is good, in water, dissolubility effectively improves, good stability.
Goal of the invention of the present invention is to be achieved through the following technical solutions:
A kind of paeonol clathrate, is characterized in that inclusion agents is the mixture of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin, and the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is 10:1～1:1, and the mol ratio of paeonol and inclusion agents is 1:2～1:10.
Preferably, while preparing injection type, the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is 0.1:1, and the mol ratio of paeonol and inclusion agents is 1:3; While preparing emulsifiable paste dosage form, the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is 10:1, and the mol ratio of paeonol and inclusion agents is 1:2; While preparing gel, the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is 5:1, and the mol ratio of paeonol and inclusion agents is 1:3.
Above-mentioned paeonol clathrate, the extraction step that it is characterized in that described paeonol comprises: get Cortex Moutan medical material, add the purified water of 10～15 times of amounts of medical material to infiltrate after 0.5～2 hour, carry out vapor distillation, collect medical material 8～10 times of amounts distillate, add NaCl, stirring and dissolving, hold over night, sucking filtration, collect paeonol crystal, dry, make.The mass ratio of described NaCl and Cortex Moutan medical material is 1:20～1:10.
Further, the extraction step of described paeonol comprises following feature: get Cortex Moutan medical material, add 15 times of amounts of medical material purified water infiltrate after 0.5 hour, carry out vapor distillation, collect the distillate of 10 times of amounts of medical material, add NaCl, stirring and dissolving, hold over night, sucking filtration, collect paeonol crystal, dry, make.The mass ratio of described NaCl and Cortex Moutan medical material is 1:15.
The preparation method of above-mentioned paeonol clathrate, comprises the steps: that paeonol is dissolved in ethanol, and the mass ratio of paeonol and ethanol is 1:5～1:10, is preferably 95% ethanol, and consumption is 1:8; Add inclusion agents to make.
Above-mentioned paeonol clathrate preparation method, comprises the following steps: get beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin and mix the inclusion agents making, add purified water and make saturated solution in 50～80 DEG C of waters bath with thermostatic control; Under agitation, slowly add 95% alcoholic solution of paeonol, constant temperature stirs 1～2 hour, stops heating, continues to be stirred to room temperature, obtains white suspension, cold preservation 10～15 hours, and sucking filtration, 40～60 DEG C of precipitate are dry, cross 80 mesh sieves, obtain paeonol clathrate.
Further, get beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin and mix the inclusion agents making, add purified water and make saturated solution in 60 DEG C of waters bath with thermostatic control; Under electric stirring, slowly add 95% alcoholic solution of paeonol, constant temperature stirs 2 hours, stops heating, continues to be stirred to room temperature, obtains white suspension, and put refrigerator and cooled and hide 12 hours, sucking filtration, 50 DEG C of precipitate are dry, cross 80 mesh sieves, obtain paeonol clathrate.
beneficial effect
Inclusion agents of the present invention after modification, tool hydrophilic, water solublity is improved, dissolubility >=100 (25 DEG C, g/100ml) in water, thus the water solublity of clathrate is increased greatly.And the present invention can be according to the physicochemical property of preparation, the ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin, the physicochemical property of flexible inclusion agents, thus obtaining the suitable clathrate of dissolubility, can reduce production costs simultaneously.For example prepare gel, can improve the ratio of hydroxypropylβ-cyclodextrin in inclusion agents, and prepare ointment, can strengthen the ratio of beta-schardinger dextrin-; Paeonol clathrate provided by the invention, good stability, is difficult for departing from; Taste masking effect is good; Inclusion rate can reach more than 80%.The present invention is easy and simple to handle, does not need specific equipment, is conducive to suitability for industrialized production.
detailed description of the invention:
Example is below to describe in further detail of the present invention, but does not mean that any restriction of the present invention.
embodiment 1
(1) extraction of paeonol: get Cortex Moutan medical material 1000g, after adding 15L purified water to infiltrate 0.5 hour, carry out vapor distillation.Collect 10L distillate, add 50gNaCl stirring and dissolving, static spending the night, sucking filtration, collects paeonol crystal, puts after dry in exsiccator and weighs, and obtains paeonol 22g.
(2) preparation of paeonol clathrate: the mixture of getting beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin 10:1 stirs and makes inclusion agents.Get the inclusion agents of 5 times of moles of paeonol, add purified water and make saturated solution in 60 DEG C of waters bath with thermostatic control; Get paeonol, after dissolving, slowly add in inclusion agents solution in 8 times of 95% ethanol, constant temperature stirs after 2 hours and stops heating, continues to be stirred to room temperature, obtains white suspension.Put refrigerator and cooled and hide 12 hours, sucking filtration, 50 DEG C of precipitate are dry, cross 80 mesh sieves, obtain paeonol clathrate.
(3) assay:
Chromatographic condition and system suitability: with octadecylsilane chemically bonded silica be filler; Methanol-water (45: 55) is mobile phase; Detecting wavelength is 274 nm; Number of theoretical plate calculates and should be not less than 5000 by paeonol peak.The preparation of reference substance solution: it is appropriate that precision takes paeonol reference substance, adds methanol and makes every milliliter of solution containing 60 μ g, to obtain final product.The preparation of need testing solution: get the about 0.2g of paeonol clathrate, accurately weighed, to put in tool plug conical flask, precision adds methanol 50 ml, close plug, shakes up, weighed weight, supersound process (power 300 W, frequency 50 kHz) 30 min, let cool, weighed weight again, supplies the weight of less loss with methanol, shake up, filter, precision measures subsequent filtrate 1 ml, puts in 10 ml measuring bottles, add methanol and be diluted to scale, shake up, to obtain final product.Algoscopy is accurate reference substance solution and the each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and calculates, and to obtain final product.
(3) inclusion rate is measured: get paeonol clathrate sample appropriate (approximately containing 10mg paeonol), accurately weighed, quantitatively add 50ml petroleum ether, supersound process 15min, by adhere to or not enclose jail paeonol dissolve, filter, get subsequent filtrate, measure the paeonol content of eluting according to " assay " item method, and calculate inclusion rate.
Inclusion rate (%)=(paeonol content of paeonol content-eluting in sample) × example weight paeonol input amount × 100%
(4) enclose effect: after measured, paeonol inclusion rate is 81.3%, and taste masking effect is good.
(5) solubility test: take paeonol, the each 1g of paeonol clathrate, at 25 ± 2 DEG C, be placed in respectively 10ml, 50ml, 100ml, 1000ml, 2000 ml volumetric flasks, add purified water to scale, jolt 30 seconds every 5 minutes brute forces, observe the dissolving situation in 30 minutes.When without macroscopic microgranule, can be considered completely and dissolve.
Experimental result is as shown in the table:
| Solvents | 10ml | 50ml | 100ml | 1000ml | 2000ml |
| Paeonol 1g | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely |
| Paeonol clathrate 1g | Do not dissolve completely | Do not dissolve completely | Dissolve completely | Dissolve completely | Dissolve completely |
Solubility experiment shows, after paeonol enclose, water solublity has increased more than 20 times.
embodiment 2
Get Cortex Moutan medical material, add the purified water infiltration of 10 times of amounts of Cortex Moutan medical material after 0.5 hour, carry out vapor distillation, collect the distillate of 8 times of amounts of medical material, add NaCl, stirring and dissolving, hold over night, sucking filtration, collects paeonol crystal, dry, makes; Wherein, the mass ratio of described NaCl and Cortex Moutan medical material is 1:10.The paeonol making is dissolved in to ethanol, and the mass ratio of paeonol and ethanol is 1:5.
Get beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin and mix the inclusion agents making, add purified water and make saturated solution in 50 DEG C of waters bath with thermostatic control; Under electric stirring, slowly add the alcoholic solution of paeonol, constant temperature stirs 1 hour, stops heating, continues to be stirred to room temperature, obtains white suspension, and put refrigerator and cooled and hide 10 hours, sucking filtration, 40 DEG C of precipitate are dry, cross 80 mesh sieves, make.Wherein, the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is 10:1, and the mol ratio of paeonol and inclusion agents is 1:2.
Content assaying method, inclusion rate assay method, solubility test method are with embodiment 1.
After measured, paeonol inclusion rate is 81.2%, and taste masking effect is good.
Experimental result is as shown in the table:
| Solvents | 10ml | 50ml | 100ml | 1000ml | 2000ml |
| Paeonol 1g | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely |
| Paeonol clathrate 1g | Do not dissolve completely | Do not dissolve completely | Dissolve completely | Dissolve completely | Dissolve completely |
Solubility experiment shows, after paeonol enclose, water solublity has increased more than 20 times.
embodiment 3
Get Cortex Moutan medical material, add the purified water infiltration of 15 times of amounts of Cortex Moutan medical material after 2 hours, carry out vapor distillation, collect the distillate of 10 times of amounts of medical material, add NaCl, stirring and dissolving, hold over night, sucking filtration, collects paeonol crystal, dry, makes; Wherein, the mass ratio of described NaCl and Cortex Moutan medical material is 1:20.The paeonol making is dissolved in to ethanol, and the mass ratio of paeonol and 90% ethanol is 1:10.
Get beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin and mix the inclusion agents making, add purified water and make saturated solution in 80 DEG C of waters bath with thermostatic control; Under electric stirring, slowly add the alcoholic solution of paeonol, constant temperature stirs 2 hours, stops heating, continues to be stirred to room temperature, obtains white suspension, and put refrigerator and cooled and hide 15 hours, sucking filtration, 60 DEG C of precipitate are dry, cross 80 mesh sieves, make.Wherein, the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is 1:1, and the mol ratio of paeonol and inclusion agents is 1:10.
Content assaying method, inclusion rate assay method are with embodiment 1.
After measured, paeonol inclusion rate is 81.6%, and taste masking effect is good.
Experimental result is as shown in the table:
| Solvents | 10ml | 50ml | 100ml | 1000ml | 2000ml |
| Paeonol 1g | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely | Do not dissolve completely |
| Paeonol clathrate 1g | Do not dissolve completely | Do not dissolve completely | Dissolve completely | Dissolve completely | Dissolve completely |
Solubility experiment shows, after paeonol enclose, water solublity has increased more than 20 times.
Claims (1)
1. a preparation method for paeonol preparation, is characterized in that, according to the following steps:
Get Cortex Moutan medical material, add the purified water of 15 times of amounts of Cortex Moutan medical material to infiltrate after about 2 hours, carry out vapor distillation, collect the distillate of 10 times of amounts of medical material, add NaCl, stirring and dissolving, hold over night, sucking filtration, collects paeonol crystal, dry, makes; Wherein, the mass ratio of described NaCl and Cortex Moutan medical material is 1:20; The paeonol making is dissolved in to ethanol, and the mass ratio of paeonol and 90% ethanol is approximately 1:10;
Get beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin and mix the inclusion agents making, add purified water and make saturated solution in 80 DEG C of waters bath with thermostatic control; Under electric stirring, slowly add the alcoholic solution of paeonol, constant temperature stirs 2 hours, stops heating, continues to be stirred to room temperature, obtains white suspension, and put refrigerator and cooled and hide 15 hours, sucking filtration, 60 DEG C of left and right of precipitate are dry, cross 80 mesh sieves, make; Wherein, the mol ratio of beta-schardinger dextrin-and hydroxypropylβ-cyclodextrin is about 1:1, and the mol ratio of paeonol and inclusion agents is 1:10.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210292211.8A CN102784131B (en) | 2012-08-16 | 2012-08-16 | Paeonol inclusion compound and preparation method thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210292211.8A Division CN102784131B (en) | 2012-08-16 | 2012-08-16 | Paeonol inclusion compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103933576A true CN103933576A (en) | 2014-07-23 |
| CN103933576B CN103933576B (en) | 2016-01-20 |
Family
ID=47149852
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410125151.XA Active CN103861120B (en) | 2012-08-16 | 2012-08-16 | A kind of preparation method of enclose medicament |
| CN201210292211.8A Active CN102784131B (en) | 2012-08-16 | 2012-08-16 | Paeonol inclusion compound and preparation method thereof |
| CN201410124917.2A Active CN103933576B (en) | 2012-08-16 | 2012-08-16 | A kind of preparation method of paeonol preparation |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410125151.XA Active CN103861120B (en) | 2012-08-16 | 2012-08-16 | A kind of preparation method of enclose medicament |
| CN201210292211.8A Active CN102784131B (en) | 2012-08-16 | 2012-08-16 | Paeonol inclusion compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN103861120B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110974977A (en) * | 2019-12-17 | 2020-04-10 | 成都柏睿泰生物科技有限公司 | Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107823127A (en) * | 2017-11-01 | 2018-03-23 | 绍兴文理学院元培学院 | A kind of production method of Shenmai-dihuang oral liquid |
| CN110547465A (en) * | 2019-08-06 | 2019-12-10 | 上海麒稷健康科技有限公司 | Brain nerve nutrition composition and preparation method thereof |
| CN110841075A (en) * | 2019-11-18 | 2020-02-28 | 鲁南制药集团股份有限公司 | Preparation method of paeonol inclusion compound |
| CN112618593A (en) * | 2020-12-01 | 2021-04-09 | 广西中恒创新医药研究有限公司 | A processing method of beta-cyclodextrin inclusion atractylone in Atractylodis rhizoma medicinal material |
| CN114028341A (en) * | 2021-11-17 | 2022-02-11 | 北京康仁堂药业有限公司 | Cortex moutan formula particle and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548026A (en) * | 2003-05-24 | 2004-11-24 | 毛友昌 | Liuwei dihuang rehmanniae micropill and its prepn |
| CN102114008A (en) * | 2010-01-01 | 2011-07-06 | 江苏康缘药业股份有限公司 | Clathrate of paeonol and preparation method and quality detection method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100553629C (en) * | 2006-10-14 | 2009-10-28 | 孙国平 | The application of paeonol in preparation anti esophageal cancer medicine |
| CN101732669B (en) * | 2010-01-25 | 2012-10-03 | 南京中医药大学 | Traditional Chinese medicine used for treating gynecologic inflammation, preparation method and application thereof |
| CN102485247B (en) * | 2010-12-06 | 2014-06-04 | 株洲千金药业股份有限公司 | Traditional Chinese medicine composition used for treating gynecologic diseases, and preparation method thereof |
| CN102283911B (en) * | 2011-09-16 | 2013-03-13 | 河南省中医药研究院 | Capsule with functions of supplementing qi, activating blood circulation and calming for treating ischemic stroke |
| CN102379864A (en) * | 2011-10-28 | 2012-03-21 | 中国人民解放军第四军医大学 | Compound salvianic acid injection for treating cerebral vascular thrombosis diseases and preparation process thereof |
-
2012
- 2012-08-16 CN CN201410125151.XA patent/CN103861120B/en active Active
- 2012-08-16 CN CN201210292211.8A patent/CN102784131B/en active Active
- 2012-08-16 CN CN201410124917.2A patent/CN103933576B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548026A (en) * | 2003-05-24 | 2004-11-24 | 毛友昌 | Liuwei dihuang rehmanniae micropill and its prepn |
| CN102114008A (en) * | 2010-01-01 | 2011-07-06 | 江苏康缘药业股份有限公司 | Clathrate of paeonol and preparation method and quality detection method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110974977A (en) * | 2019-12-17 | 2020-04-10 | 成都柏睿泰生物科技有限公司 | Drying method of paeonol β -cyclodextrin inclusion compound in preparation of cortex moutan formula granules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103861120B (en) | 2015-12-09 |
| CN103861120A (en) | 2014-06-18 |
| CN103933576B (en) | 2016-01-20 |
| CN102784131B (en) | 2014-04-16 |
| CN102784131A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103933576B (en) | A kind of preparation method of paeonol preparation | |
| CN102048693B (en) | Liposome having internal aqueous phases of benzenesulfonic acid derivatives | |
| CN104800161B (en) | A kind of OPC flexible nano-liposomes prepared using surfactant and preparation method thereof | |
| Pagano et al. | Development of sodium carboxymethyl cellulose based polymeric microparticles for in situ hydrogel wound dressing formation | |
| Ren et al. | Formulation development and molecular mechanism characterization of long-acting patches of asenapine for efficient delivery by combining API-ILs strategy and controlled-release polymers | |
| CN104644553A (en) | Tanshinone IIA micro-emulsion preparation, tanshinone IIA micro-emulsion gel preparation and preparation methods of preparations | |
| CN103239586A (en) | Flavored agastache turbidity-dispelling external preparation as well as preparation method and application thereof | |
| CN113143811A (en) | A kind of preparation method of peony flower extract complex liposome | |
| Liu et al. | Investigation on the preparation, characteristics, and controlled release model of paeonol-loaded liposome in carbomer hydrogel | |
| CN103910762A (en) | Preparation method of miriplatin | |
| CN108324686A (en) | A kind of ellagic acid is from micro emulsion and preparation method thereof | |
| CN102847164B (en) | Application of chrysalis oil in improving small molecule drug bioavailability | |
| CN104337844A (en) | Venenum bufonis extractive and application of preparation of venenum bufonis extractive to preparing medicines for treating melanoma | |
| CN102885702B (en) | Application of evodiamine to preparation of anti-ultraviolet composition | |
| CN104237404A (en) | Method for measuring content of ferulic acid in Yixinshu preparations | |
| CN111249223B (en) | Propranolol hydrochloride cubic liquid crystal gel and preparation method thereof | |
| CN103690560A (en) | Invert sugar electrolyte injection pharmaceutical composition and preparation method thereof | |
| CN116617203B (en) | Self-emulsifying microemulsion composition and preparation method and application thereof | |
| CN106967139B (en) | A kind of lamp-dish flower acetic crystal form and preparation method thereof | |
| Xiao et al. | Mixed-ligand coordination polymers: structural diversity and protective effect on cardiac arrest induced by anesthesia via inducing Sirt1 pathway | |
| CN103091408A (en) | Method for determining content of hesperidin in Citrus Bioflavonoids | |
| CN106841464A (en) | Ellagic acid and 3,3` dimethoxy ellagic acid detection method of content in a kind of China fir parasitism | |
| CN102344432A (en) | Preparation method for epigallocatechin gallate (EGCG) methylated derivatives | |
| CN108459113A (en) | A kind of vitamin C component in food rapid detection method | |
| CN105311644A (en) | Method for preparing glycyrrhizin modified paclitaxel liposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 442500 Shiyan city of Hubei province Yunxian Tiansheng Road Economic Development Zone No. 1 Patentee after: HUBEI TIANSHENG PHARMACEUTICAL CO., LTD. Address before: 442500, 171, East Ling Ling Street, meteorite County, Hubei, Shiyan Patentee before: Sky, Hubei Sheng Kangdi pharmaceutical Co. Ltd |